CTN-BI-Vacc-C5-2011/1
Status:Ongoing
Phase:I/II
Principal Investigator(s):Vidar Wendel-Hansen, MD PhD - Bionor Pharma AS
Objective:To evaluate safety of the vaccination regimens. To evaluate C5-specific humoral immune responses (antibodies), T cell responses, T cell activation markers and other immune markers.
Prevention Option(s):Therapeutic Vaccines
Study Design:Non-randomized, Open label
Arms and Assigned Interventions
DescriptionArm A: Vacc-C5 /GM-CSF. Vacc-C5 with GM-CSF as adjuvant.
Mode of DeliveryIntradermal
ARMsExperimental
Official Code:
NCT01627678
Trial Sponsors:
Bionor Immuno AS
Start Date
End Date
September 30, 2012
November 30, 2013
Enrollment:36
Age range:
18 Years ↔
55 Years
Population:Cisgender Men, Cisgender Women, People Living with HIV